Effects of various inhibitors on the TF-induced clotting time in human plasma
Inhibitor . | [Inhibitor]1.5 × CT,*nM . | Relative potency† . |
---|---|---|
TAP-ANV | 0.80 | 86 |
ANV 6L15 | 6.0 | 12 |
ANV-KAPP | 9.4 | 7.3 |
ANV-KKTFPI | 11 | 6.3 |
ANV | 29 | 2.4 |
TAP | 68 | 1 |
TFPI | 69 | 1 |
E. coli TFPI1-160 | 2750 | 0.025 |
6L15 | 5900 | 0.012 |
Inhibitor . | [Inhibitor]1.5 × CT,*nM . | Relative potency† . |
---|---|---|
TAP-ANV | 0.80 | 86 |
ANV 6L15 | 6.0 | 12 |
ANV-KAPP | 9.4 | 7.3 |
ANV-KKTFPI | 11 | 6.3 |
ANV | 29 | 2.4 |
TAP | 68 | 1 |
TFPI | 69 | 1 |
E. coli TFPI1-160 | 2750 | 0.025 |
6L15 | 5900 | 0.012 |
Pooled human plasma (100 μL) was mixed with an equal volume of an inhibitor dissolved in buffer (10 mM Tris, pH 7.4; 0.15 M NaCl; 1 mg/mL BSA; 0.02% NaN3) at varying concentrations. Dade Innovin was diluted 1:100 with buffer (75 mM NaCl, 12.5 mM CaCl2, 0.5 mg/mL BSA, 0.02% NaN3) for the assay. Clotting times were determined with an ACL 200 coagulation analyzer.
Concentration of inhibitor that prolongs the TF-induced clotting time 1.5-fold relative to control (ie, from 40.7 to 61.1 seconds)
Calculated by dividing [Inhibitor]1.5 × CT for TFPI by the value for the other specified inhibitor